Meloxicam should not be taken if you are pregnant, planning to become pregnant, or breastfeeding. Anyone who has had ulcers, kidney or liver disease or problems, or stomach bleeding should not take this medication. It should be taken with extreme caution for people with fluid retention and heart failure. Older adults, those who are in poor health, and those who have been taking NSAIDs for a long time are more likely to experience these side effects.
Meloxicam is not addictive, but it interacts poorly with blood thinners and could lead to bleeding. Alcohol should be avoided as much as possible while taking meloxicam because it increases the risk of getting stomach ulcers.
More serious risk factors associated with taking meloxicam include chest pain, infrequent urination or not urinating at all, coughing up blood or vomit that looks like coffee grounds, and black, bloody, or tarry stools. You should stop taking meloxicam and call your doctor immediately if you experience any of these side effects.
This list of side effects is not comprehensive. Ask a healthcare professional for more details regarding the possible side effects of meloxicam. This medication guide is a great resource that lists FDA warnings, adverse reactions, drug interactions, and general drug information as it relates to meloxicam.
There are multiple drug alternatives to meloxicam that function in a similar way. Some medications like Aleve and Tylenol are available over-the-counter. Speaking with a medical professional can help you determine which medication is best for treating your individual arthritis pain. Many natural and home remedies can help treat arthritis symptoms and may be an alternative to meloxicam for some people.
Certain herbal supplements have anti-inflammatory properties, and natural treatments like massage therapy, acupuncture, or chiropractic adjustments can help manage pain symptoms. Skip to main content Search for a topic or drug. What is meloxicam and what is it used for? By SingleCare Team Dec.
Want the best price on Meloxicam? The prevalence of OA increases with age, resulting not only in considerable pain and disability, but also in substantial medical costs. Osteoarthritis is characterized by pain both on motion and at rest, stiffness after inactivity, impaired mobility, and inflammation, especially in the early stages.
No specific cause has been identified and no cures are available; treatment is aimed at alleviation of symptoms. Symptomatic treatment may consist of nonpharmacologic as well as pharmacologic interventions, including the use of nonsteroidal anti-inflammatory drugs NSAIDs. Use of NSAIDs has been associated with a risk of serious and life-threatening gastrointestinal GI adverse events, such as perforation and bleeding.
While these adverse effects do not correlate with GI bleeding, they do impact the performance of daily functions and contribute to increased medical costs resulting from the need for additional physician visits and changes in medication. It has been approved for use in more than 80 countries for the treatment of OA, rheumatoid arthritis, and ankylosing spondylitis.
In vitro and in vivo tests have shown that meloxicam is a cyclooxygenase COX inhibitor that demonstrates more COX-2 inhibition than COX-1 inhibition at therapeutic concentrations. Steady-state plasma concentrations are reached after 3 to 5 days with administration of 7. The objective of the present study was to evaluate the safety and efficacy of 3 dosages of meloxicam 3.
Patients enrolled in this study met the following criteria: current NSAID user at least 40 years of age, at least a 3-month history of OA of the knee or hip confirmed by x-ray and by clinical signs and symptoms, and pain on movement in the target joint. Patients with a history of upper GI perforations, ulcers, or peptic ulcer bleeding were not excluded unless the event had occurred within the 6 months prior to enrollment. Subsequent to enrollment, an NSAID-free period of at least 3 days was initiated, during which demonstration of a flare was required.
A flare was defined as a worsening of disease activity from initial screening that met the following criteria: at least 1 grade deterioration in the investigator's global assessment of disease activity; an increase of 10 mm or greater on a mm visual analog scale VAS for the patient's global assessment of disease activity; and an increase greater than 35 mm on a mm VAS in the patient's overall assessment of pain.
Upon flare, the patient was scheduled for baseline evaluation and initiation of treatment. Once treatment was initiated, efficacy and safety evaluations were performed at 2, 4, 8, and 12 weeks or at early termination. Diclofenac was chosen as an active comparator to establish sensitivity of the efficacy end points based on its' known efficacy and frequent clinical use. Meloxicam and placebo were given once in the morning after food, and diclofenac was administered in the morning and in the evening after food.
The trial was approved by the appropriate ethics committees and was conducted in accordance with the latest version of the Declaration of Helsinki and under the guidelines for good clinical practice.
All patients gave written informed consent. Tolerability was assessed by recording the incidence, duration, and intensity of all adverse events and patient withdrawals due to adverse events. For each adverse event, the investigator assessed whether or not the event was drug related. The need for treatment of the adverse event and the action taken with the study drug subsequent to the adverse event also were recorded. Safety was further assessed by vital signs, physical examinations, and clinical laboratory tests, including hematologic analysis and standard chemistry tests uric acid, phosphorus, and calcium , serum creatinine levels, serum urea nitrogen levels, and both aspartate and alanine aminotransferase levels, to identify any effects on renal or hepatic function.
In addition, a hour urine collection was done prior to administering the first study medication and at the trial conclusion to determine the patient's creatinine clearance.
Several primary and secondary variables were used to evaluate efficacy. Primary variables included the Western Ontario and McMaster University Osteoarthritis WOMAC index and the following flare criteria end points: patient's and investigator's global assessment of disease activity and patient's overall assessment of pain. In addition to the WOMAC subscale for pain, the patient's overall pain for the prior 24 hours was assessed using a mm VAS 0, no pain; , worst pain.
A mm VAS was also used in the patient's global assessments of disease activity, with the best outcome fixed at 0 and the worst outcome fixed at The investigator's global assessment of disease activity used a 5-point verbal rating scale ranging from 0 to 4: none, mild, moderate, severe, and very severe and was performed after and blinded to the patient's global assessment. Secondary efficacy variables included assessment of pain both at rest and on movement for the previous 24 hours in the target joint.
As in the primary efficacy end point for pain, a mm VAS was used. Use of rescue medication acetaminophen was permitted, and the rate of consumption on treatment was included as a secondary efficacy variable. At 12 weeks or with early termination, a final global assessment of efficacy was performed by the patient and the investigator using a 4-point verbal rating scale good, satisfactory, not satisfactory, and poor. In addition, the patient's status with regard to the change in arthritic condition was determined by asking the patient to rate his or her current condition compared with the condition at the start of the trial as improved, unchanged, or deteriorated.
Time to first GI adverse event was analyzed with log-rank tests and Kaplan-Meier estimates. Primary efficacy analyses were performed based on the intent-to-treat principle, including all treated patients with at least one on-treatment evaluation.
Both the patient's last visit assessment last observation carried forward and the weighted mean of all on-trial assessments were analyzed. Analysis of variance models, including treatment, target joint, and center, were used for all variables assessed by VAS, as well as for the WOMAC index for pain, stiffness, physical function, and total score. These variables were analyzed as change from baseline intensity of flare.
Secondary efficacy variables were also analyzed applying the intent-to-treat principle. For those variables assessed by VAS pain on movement and pain at rest , analyses were performed using analysis of variance on data for change from baseline in a manner similar to that for the primary analyses.
For rescue medication use, analysis of covariance was performed, with weekly average use as the dependent variable and use during flare as a covariate. The patients' and investigators' final global assessment of efficacy and the patients' assessment of change in arthritic condition were analyzed using stratified rank sum test procedures, stratified by center. Time to early discontinuation overall, for adverse events, and for lack of efficacy was analyzed with log-rank tests and Kaplan-Meier estimates.
Time to first GI adverse event was analyzed with adjustment for exposure by applying log-rank tests and the Kaplan-Meier algorithm. Among a total of patients enrolled and screened by 61 study centers, patients were randomized into the trial, and patients initiated treatment. The demographic and disease characteristics were similar across the treatment groups Table 1.
The incidence of all adverse events was comparable among the 3 meloxicam groups Meloxicam did not demonstrate any dose-dependent increase in total adverse events or adverse events grouped by preferred terms Table 2 based on the World Health Organization adverse event coding thesaurus World Health Organization Adverse Event Dictionary , September Gastrointestinal adverse events were the most frequently reported events by system organ class Table 2.
Likewise, the percentage of withdrawals as a result of GI adverse events was similar among the meloxicam groups 3. A serious adverse event was defined as any fatal or immediately life-threatening clinical experience or disabling event, or one that required prolonged inpatient hospitalization, whether or not it was judged to be related to treatment. Only 1 GI event was considered to be a serious adverse event and also thought to be related to study medication.
Both NSAIDs can cause side effects such as abdominal pain, diarrhea, nausea, indigestion, and flatulence gas. Both medications can also cause headache, dizziness, back pain, and flu-like symptoms among others. More serious side effects may include altered blood pressure, heart arrhythmias, and impaired liver function. Although rare, allergic reactions are also possible and include trouble breathing, chest pain, swelling, and hives.
Both meloxicam and Celebrex can interact with blood thinners such as low dose aspirin, warfarin, and other drugs. Taking these medications together can increase the risk of bleeding and stomach ulcers. Meloxicam and Celebrex can also interact with diuretics and certain blood pressure medications such as ACE inhibitors, angiotensin receptor blockers ARBs , and beta blockers. Taking these drugs together may increase the risk of kidney problems.
Meloxicam and Celebrex also interact with lithium, methotrexate, and cyclosporine. Taking these drugs together can lead to increased toxicity. Consult a doctor with all medications you may be takin g.
Meloxicam and Celebrex both have warnings on their drug labels that indicate a greater risk of gastrointestinal GI and cardiovascular effects. They can also increase the risk of heart attacks and stroke. If you have a history of high blood pressure, heart disease, or other conditions, you may be at a higher risk. Both meloxicam and Celebrex are not recommended in those who have undergone coronary artery bypass graft CABG surgery.
Meloxicam and Celebrex should be monitored in those with kidney or liver problems as they can make these issues worse.
Meloxicam is a generic NSAID medication that can treat inflammation, pain, and swelling from arthritis. It can also treat arthritis of the spine as well as menstrual cramps. Celebrex is taken once or twice daily. However, they are not the same. They have different uses and may be taken differently depending on the condition being treated.
Meloxicam and Celebrex are both effective depending on their use. Meloxicam may be preferred for its once-daily dosing. Celebrex may be preferred for someone who has ankylosing spondylitis or menstrual cramps. Meloxicam and Celebrex should be avoided in women who are pregnant. It is not recommended to use meloxicam or Celebrex with alcohol.
0コメント